Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | EBP | Q15125 | 1/20 | 0.54 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15503757 | 0.82 | MEN1 (1.00) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL762416 | 0.82 | KMT2A (0.74) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL266466 | 0.81 | MEN1 (0.77) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL15014573 | 0.81 | MEN1 (0.77) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL1229961 | 0.80 | USP2 (0.69) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL421626 | 0.80 | USP2 (0.63) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL4212319 | 0.79 | MEN1 (0.75) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL266385 | 0.79 | LMNA (1.00) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL2839822 | 0.79 | MEN1 (0.75) | MEN1KMT2ATDP1LMNAMCOLN3 | |
| SCHEMBL16058234 | 0.79 | POLB (0.66) | MEN1KMT2ALMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100372532-C | Imidazolin-2-ylaminophenyl amides as IP antagonists. | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| CN-1780617-A | Imidazolin-2-ylaminophenyl amides as IP antagonists. | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | MEN1 3607/4885KMT2A 4094/4885TDP1 4387/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | MEN1 3460/4885KMT2A 3904/4885TDP1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.